Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 7/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024935 | 0.91 | TP53 (0.64) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL7169230 | 0.91 | LMNA (0.63) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL3030712 | 0.91 | CHRNA7 (0.68) | LMNATP53MAPTCHRNA7 | |
| SCHEMBL3025956 | 0.91 | CHRNA7 (0.68) | LMNATP53MAPTCHRNA7 | |
| SCHEMBL3036106 | 0.90 | CHRNA7 (0.67) | LMNATP53MAPTCHRNA7 | |
| SCHEMBL3030312 | 0.89 | CHRNA7 (0.68) | TP53MAPTTHRBCHRNA7 | |
| SCHEMBL3013319 | 0.89 | CHRNA7 (0.53) | LMNATP53MAPTCHRNA7 | |
| SCHEMBL3030232 | 0.89 | TP53 (0.61) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL3030227 | 0.89 | TP53 (0.63) | LMNATP53MAPTPOLBTHRB | |
| SCHEMBL3025415 | 0.87 | CHRNA7 (0.52) | LMNATP53MAPTCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | claimed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | claimed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | claimed |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-01-16 | — | — | US | claimed |
| EP-1244620-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-10-02 | — | — | EP | claimed |
| WO-2001047880-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | claimed |
| US-8609713-B2 | Pyrrole derivatives and their methods of use | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | ABBOTT LABORATORIES (US) | 2010-08-26 | — | — | US | disclosed |
| US-7741364-B2 | Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate | ABBOTT LABORATORIES (US) | 2010-06-22 | — | — | US | disclosed |
| EP-2041085-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | Abbott Laboratories (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2008002974-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| US-6569890-B2 | Antiinflamamtory agents | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| EP-1244620-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6372777-B1 | ENZYME INHIBITORS TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, AS WELL AS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, | ICOS CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001047880-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064695-A1 | PYRROLE DERIVATIVES AND THEIR METHODS OF USE | PYCR1, PPOX, DHPS | LMNA 3511/4885TP53 902/4885MAPT 1215/4885 |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE4C | LMNA 4631/4885TP53 4526/4885MAPT 2040/4885 |
| US-20100216748-A1 | Pyrrole Derivatives and Their Methods of Use | PYCR1, PPOX, DHPS | LMNA 3511/4885TP53 902/4885MAPT 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.